Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280209 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS ONE, 2023. Verfasst von Patricia Volkow und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Department, Instituto Nacional de Cancerología, Mexico City, Mexico. Hauptthemen laut MEDLINE: Sarcoma, Kaposi, HIV Infections, Herpesvirus 8, Human, Anemia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Mexican Congress Equity & Gender Commission.
Abstract (Originalsprache)
Introduction
High HHV-8 viral load (VL) in Kaposi Sarcoma (KS) has been associated with Severe Immune Reconstitution Inflammatory Syndrome (Severe-IRIS-KS), which can occur after initiating cART, and leads to high mortality, particularly in patients with pulmonary involvement. We investigate if valganciclovir (as an anti-HHV-8 agent) initiated before cART reduces the mortality associated with Severe-IRIS-KS and the incidence of Severe-IRIS-KS.
Methods
Open-label parallel-group randomized clinical trial in AIDS cART naïve patients with disseminated KS (DKS) as defined by at least two of the following: pulmonary, lymph-node, or gastrointestinal involvement, lymphedema, or ≥30 skin lesions. In the experimental group (EG), patients received valganciclovir 900 mg BID four weeks before cART and continued until week 48; in the control group (CG), cART was initiated on week 0. Non-severe-IRIS-KS was defined as: an increase in the number of lesions plus a decrease of ≥one log10 HIV-VL, or an increase of ≥50cells/mm3 or ≥2-fold in baseline CD4+cells. Severe-IRIS-KS was defined as abrupt clinical worsening of KS lesions and/or fever after ruling out another infection following cART initiation, and at least three of the following: thrombocytopenia, anemia, hyponatremia, or hypoalbuminemia.
Results
40 patients were randomized and 37 completed the study. In the ITT analysis, at 48 weeks, total mortality was the same in both groups (3/20), severe-IRIS-KS attributable mortality was 0/20 in the EG, compared with 3/20 in the CG (p = 0.09), similar to the per-protocol analysis: 0/18 in the EG, and 3/19 in the control group (p = 0.09). The crude incidence rate of severe-IRIS-KS was four patients developed a total of 12 episodes of Severe-IRIS-KS in the CG and two patients developed one episode each in the EG. Mortality in patients with pulmonary KS was nil in the EG (0/5) compared with 3/4 in the CG (P = 0.048). No difference was found between groups in the number of non-S-IRIS-KS events. Among survivors at week 48, 82% achieved >80% remission.
Conclusions
Although mortality attributable to KS was lower in the EG the difference was not statistically significant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Disease Department, Instituto Nacional de Cancerología, Mexico City, Mexico.
- Integrative Inmunology Laboratory, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
- Cytogenetic Laboratory, Instituto Nacional de Cancerología, Mexico City, Mexico.
- Department of Research on Tobacco and COPD, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico.
ORCID-Profile: Patricia Volkow, Leslie Chavez Galan
Förderung
- The Mexican Congress Equity & Gender Commission
Zitieren
APA
Volkow, P., Chavez Galan, L., Ramon-Luing, L., Cruz-Velazquez, J., Cornejo-Juarez, P., Sada-Ovalle, I., Perez-Padilla, R., Islas-Muñoz, B., & Kaposi Sarcoma Study Group (2023). Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0280209
Vancouver
Volkow P, Chavez Galan L, Ramon-Luing L, Cruz-Velazquez J, Cornejo-Juarez P, Sada-Ovalle I, et al. Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial. PLOS ONE. 2023. doi:10.1371/journal.pone.0280209
BibTeX
@article{Volkow2023,
author = {Volkow, Patricia and Chavez Galan, Leslie and Ramon-Luing, Lucero and Cruz-Velazquez, Judith and Cornejo-Juarez, Patricia and Sada-Ovalle, Isabel and Perez-Padilla, Rogelio and Islas-Muñoz, Beda and Kaposi Sarcoma Study Group, Kaposi Sarcoma Study Group},
title = {Impact of valganciclovir therapy on severe IRIS-Kaposi Sarcoma mortality: An open-label, parallel, randomized controlled trial},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280209}
}
EUVIMED